Lufthansa Q1 Loss Narrows as Strong Summer Travel Demand Boosts Outlook 
Philips Reaffirms 2026 Outlook After Strong Q1 Sales and Margin Beat 
Strategy Reports Q1 Loss as Bitcoin Holdings Trigger $14.46 Billion Unrealized Hit 
Samsung Appoints New TV Business Head Amid Rising Competition from Chinese Rivals 
Strategy Hints at Bitcoin Sales to Cover Dividends After Massive Q1 Loss 
Continental AG Shares Jump After Q1 Profit Beats Expectations 
Pinterest Stock Surges After Strong Q1 2026 Earnings Beat Expectations 
AMD Q1 Earnings Surge on AI Demand, Stock Jumps After Strong Guidance 
Novo Nordisk Raises 2026 Outlook on Strong Wegovy Demand 
Palantir Reports Record Growth, Raises 2026 Revenue Outlook Above Expectations 
BHP Attracts AI-Focused Investors as Copper Demand Surges 
Berkshire Hathaway Meeting Sees Shift as Greg Abel Steps Into Leadership Spotlight 
Regis Resources and Vault Minerals to Merge in $10.7B Gold Deal 
Supermicro Forecasts Strong Q4 Revenue Growth as AI Server Demand Surges 
Anthropic’s $1.5B AI Venture with Wall Street Firms Targets Private Equity Market 
Hugo Boss Beats Q1 Profit Expectations Despite Market Headwinds 
BMW Keeps 2026 Outlook Despite 25% Profit Drop Amid Tariff Pressure 
Heidelberg, Germany, May 3, 2018 - Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, announced today that Dr. Adi Hoess, CEO, will present at Deutsche Bank's 43rd Annual Health Care Conference on Tuesday, May 8, 2018 at 10:40 am ET.
A live webcast of the conference presentation can be accessed through the "Events" section on the "Investors & Media" page of the Affimed website at www.affimed.com/events.php. A replay of the presentation will be available from Affimed's website for 30 days following the conference.
About Affimed N.V.
Affimed (Nasdaq: AFMD) engineers targeted immunotherapies, seeking to cure patients by harnessing the power of innate and adaptive immunity (NK and T cells). We are developing single and combination therapies to treat cancers and other life-threatening diseases. For more information, please visit www.affimed.com.
Contact:
Anca Alexandru, Head of Communications, EU IR
Phone: +49 6221 64793341
E-Mail: [email protected], I[email protected]
